ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
WILLIAM WONG MD

Cardiovascular Disease

1,505

$47.2K

219
192 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

7%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 28%

$31
Average prescription price

Avg: $67

MOHINDER POONIA MD

Cardiovascular Disease

9,978

$564K

402
308 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

23%
patients receiving schedule three controlled substances

Avg: 2%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$57
Average prescription price

Avg: $67

WINDGROVE DANIEL M.D

Cardiovascular Disease

2,655

$94K

82
42 are 65+

22%
patients receiving schedule two controlled substances

Avg: 0%

52%
patients receiving schedule three controlled substances

Avg: 2%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$35
Average prescription price

Avg: $67

AARON JORDAN MD

Cardiovascular Disease

16,694

$704K

633
541 are 65+

7%
patients receiving schedule two controlled substances

Avg: 0%

27%
patients receiving schedule three controlled substances

Avg: 2%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 28%

$42
Average prescription price

Avg: $67

HONG-LING LEE M.D.

Cardiovascular Disease

6,365

$397K

268
220 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

22%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$62
Average prescription price

Avg: $67

T.S.S RAJAN M.D

Cardiovascular Disease

2,238

$74.8K

70
57 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 28%

$33
Average prescription price

Avg: $67

GUY CURTIS M.D.

Cardiovascular Disease

4,487

$231K

361
348 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$51
Average prescription price

Avg: $67

PRAKASH PATEL MD

Cardiovascular Disease

6,361

$284K

367
311 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

10%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$45
Average prescription price

Avg: $67

PEDRO DIAZ M.D.

Cardiovascular Disease

3,281

$160K

173
131 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 28%

$49
Average prescription price

Avg: $67

ROBERT KALMANSOHN M.D.

Cardiovascular Disease

741

$28K

60
51 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 28%

$38
Average prescription price

Avg: $67

JULIUS WOYTHALER M.D.

Cardiovascular Disease

1,519

$96K

70
69 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 28%

$63
Average prescription price

Avg: $67

OSCAR ZAMBRANO M.D.

Cardiovascular Disease

22,733

$918K

1008
870 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

12%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 28%

$40
Average prescription price

Avg: $67

ALYN ANDERSON M.D.

Cardiovascular Disease

7,682

$591K

446
397 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 28%

$77
Average prescription price

Avg: $67

FAYAZ ASGHAR MD

Cardiovascular Disease

4,057

$330K

217
194 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$81
Average prescription price

Avg: $67

PRAKASH SHENOY M.D.

Cardiovascular Disease

1,968

$74.2K

101
94 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 28%

$38
Average prescription price

Avg: $67

ADEL METRY M.D.

Cardiovascular Disease

2,176

$95.4K

136
104 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

8%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 28%

$44
Average prescription price

Avg: $67

GUSTIN HO M.D.

Cardiovascular Disease

21,804

$1.49M

1208
1174 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$68
Average prescription price

Avg: $67

JOSE ROCAMORA MD

Cardiovascular Disease

45,055

$2.14M

1473
1174 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

21%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$48
Average prescription price

Avg: $67

EMMANUEL VASILOMANOLAKIS MD

Cardiovascular Disease

3,160

$131K

209
186 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 28%

$41
Average prescription price

Avg: $67

ANURADHA KHURANA MD

Cardiovascular Disease

1,429

$115K

408
370 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

11%
prescriptions for brand name drugs

Avg: 28%

$81
Average prescription price

Avg: $67

AMRITLAL RANAVAT M.D.

Cardiovascular Disease

1,156

$34.8K

60
51 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 28%

$30
Average prescription price

Avg: $67

JUN CHIONG M.D., M.P.H.

Cardiovascular Disease

3,981

$139K

352
243 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

8%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 28%

$35
Average prescription price

Avg: $67

SIVA ARUNASALAM

Cardiovascular Disease

10,589

$1.22M

863
667 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 28%

$115
Average prescription price

Avg: $67

MIRKO GIACONI

Cardiovascular Disease

8,352

$656K

312
260 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

12%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$78
Average prescription price

Avg: $67

CYNTHIA THAIK M.D.

Cardiovascular Disease

1,102

$92.5K

105
86 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$84
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank